JAGSNPHARM vs JBCHEPHARM: Stock Comparison
Jagsonpal Pharmaceuticals Limited vs JB Chemicals & Pharmaceuticals Limited
Live data: 27 July 2026, 10:41 AM IST • Source: NSE and company filings
JB Chemicals & Pharmaceuticals Limited is the larger company by market capitalisation. Jagsonpal Pharmaceuticals Limited shows a lower P/E and faster revenue growth, while JB Chemicals & Pharmaceuticals Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Jagsonpal Pharmaceuticals Limited and JB Chemicals & Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | JAGSNPHARM | JBCHEPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | JAGSNPHARM | JBCHEPHARM |
|---|---|---|
| Live Price | ₹221.91 | ₹2,408.9 |
| Day Change | 0.14% | -3.87% |
| Volume | 15,097 | 47.79 L |
| 52-Week High | ₹301.65 | ₹2,525.5 |
| 52-Week Low | ₹155 | ₹1,638.5 |
| Distance from 52W High | -26.43% | -4.62% |
Valuation
| Metric | JAGSNPHARM | JBCHEPHARM |
|---|---|---|
| Market Cap | ₹1,478 Cr | ₹38,731 Cr |
| P/E Ratio | 34.56x | 54.59x |
| P/B Ratio | 5.39x | 9.31x |
| EPS | ₹6.32 | ₹44.49 |
| Book Value | ₹39.4 | ₹259.05 |
| Dividend Yield | 1.13% | 1.19% |
Growth
| Metric | JAGSNPHARM | JBCHEPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 9.6% | -4.8% |
| EPS Growth (TTM YoY) | 23.8% | -31% |
| Qtr Sales Growth | 9.63% | -4.77% |
| Qtr Profit Growth | 30% | -17% |
Profitability & Leverage
| Metric | JAGSNPHARM | JBCHEPHARM |
|---|---|---|
| ROE | 17.3% | 18.9% |
| ROCE | 22.7% | 25.4% |
| Net Margin | 15% | 17.1% |
| Operating Margin | 20.2% | 26.7% |
| Debt to Equity | 0.03x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | JAGSNPHARM | JBCHEPHARM |
|---|---|---|
| Promoter Holding | 25.55%▲ 0.43 pp | 48.8%▲ 48.8 pp |
| FII Holding | 2.3%▼ 0.14 pp | 16.33%▲ 1.45 pp |
| DII Holding | 0.62%▲ 0.4 pp | 21.38%▼ 1.98 pp |
| Public Holding | 28.03%▼ 1.42 pp | 13.48%▼ 0.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Jagsonpal Pharmaceuticals Limited and JB Chemicals & Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.